McKesson Corporation, a healthcare services and IT company, is set to announce its Q3 earnings for 2026 on Feb. 4. Analysts expect a profit of $9.19 per share, up 14.5% from the year-ago quarter. For fiscal 2026, profit is expected to be $38.61 per share, up 16.8% from fiscal 2025. Shares of MCK have surged 38% over the past year, outperforming the S&P 500 and XLV ETF. In Q2, the company’s EPS exceeded estimates by 10.5%, driven by higher prescription volumes and increased drug distribution. Wall Street analysts are highly optimistic about MCK’s stock, with a “Strong Buy” rating overall and a mean price target of $940.94.

Read more at Barchart: What You Need to Know Ahead of McKesson Corporation’s Earnings Release